Scopolamine Articles
Cephalon to acquire Anesta in $444M deal
18 July 2000
FDA rejects Nastech's New Drug Application for motion sickness drug
24 February 2000
Nastech files NDA for intranasal scopolamine
21 December 1999
Nastech to file NDA for motion sickness drug
12 July 1999
Novartis To Relaunch Scopolamine Patches
13 November 1997
Noven Files Two INDs
16 October 1997
Cognitive Enhancers Unveiled At ASM
21 November 1994
Showing 1-7 of 7 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
